SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to its FDA-approved drug for a specific type of leukemia, though the drug carries warnings about potentially fatal side effects, leading to concerns about its safety profile.  Despite these concerns, some community members believe the drug's approval doubles its addressable market and view this as a long-term play, while others suggest a potential acquisition. Discussions also include potential market manipulation and the possibility of a short squeeze.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending due to retail investors targeting a potential short squeeze, evidenced by high borrowing costs and significant social media discussion around depleting float. The community is actively discussing strategies to pressure short sellers, with some users calling for a coordinated effort to recall lent shares. Bullish sentiment seems tied to expectations around insiders increasing their positions.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as analysts are raising price targets, citing increasing DRAM prices and AI demand, with UBS setting a target of $245 and Citi at $240. The community is closely watching for a breakout above $200 and speculating about potential partnerships, particularly with OpenAI, while also weighing its removal from the Chinese server market. Bullish sentiment revolves around Micron's undervalued status compared to its peers and the expectation of strong earnings reports driving further gains.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford's stock is trending downwards as a fire at a key aluminum supplier is expected to disrupt production, particularly for the profitable F-150 trucks. The community is debating whether this dip is an overreaction, a buying opportunity, or a sign of deeper issues with Ford's supply chain management and future guidance. Discussions also involve potential tariff relief and its impact on Ford's financials amid the aluminum shortage.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a significant surge potentially fueled by news of insider buying and a milestone payment from Merck related to their Alzheimer's program. The community is actively discussing the low float and potential for a short squeeze, with some speculating about a potential run to double digits. However, some traders caution about potential dilution.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to increased discussion around its progress in quantum computing, particularly error correction, and its potential impact on AI. The community is weighing the significance of IBM's partnerships, like the one with AMD, and debating whether its established position gives it an edge over smaller quantum computing companies. Some are calling IBM undervalued given its free cash flow and position in the quantum computing space.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as the community discusses its continued strength in the semiconductor market, fueled by AI prospects and key partnerships, even amidst concerns of bubble territory. Recent advancements in graphics technologies and speculation around upcoming announcements at the GTC conference are adding to the bullish sentiment. Traders are closely watching for a potential breakout towards the $200 level, while also weighing the impact of broader market factors and potential government actions.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining Corp is trending amid discussions of a potential Newmont takeover of Barrick's Nevada gold assets and Scotiabank upgrading its rating to Sector Outperform. Community members are also discussing the company's solid liquidity and potential merger opportunities. Some are also pointing out recent job cuts with others expecting gold to soar further.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the community discusses potential government investment in the quantum computing sector following recent news, despite some skepticism. Community members are debating the company's valuation and future prospects in light of competition and potential dilution, while also pointing out the CEO's equity stake. Technical traders are watching key price levels for potential breakouts or breakdowns.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk ($TTD) is experiencing volatility, with community members noting a lack of clear news catalysts for recent price swings. Despite broader market rallies, $TTD struggles to hold gains, leading to frustration among investors and speculation about market manipulation. Some investors point to a potential inverse head and shoulders pattern and analyst price target reiterations as positives, while others highlight the company's upcoming earnings release and potential benefits from shifts in the ad tech landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Protalix BioTherapeutics (PLX) and Chiesi Global Rare Diseases announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve a new dosing regimen for Elfabrio.The company was seeking approval of a dosing regimen of 2 mg/kg body weight infused every four weeks for Elfabrio. The currently approved dosing regimen in the European Union is 1 mg/kg body weight infused every two weeks for the treatment of adults with confirmed Fabry disease, a rare genetic disorder leading to the buildup of a fatty substance called globotriaosylceramide in cells throughout the body.Fabry disease can cause a range of serious signs and symptoms, including fatigue, chronic pain, gastrointestinal issues, decreased ability to sweat, progressive kidney failure, heart complications, and increased risk of stroke. It affects both males and females and is caused by a deficiency of the enzyme alpha-galactosidase A.However, Protalix CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168523/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-Biotherapeutics-Acknowledge-CHMP-Negative-Opinion-on-Every-Four-Week-Dosing-Regimen-of-Elfabrio-pegunigalsidase-alfa-in-the-EU.html">said</a> that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease. The two companies also clarified that they intend to keep working together.Shares of PLX dropped 28% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PLX">PLX stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.Protalix submitted the data to the committee for review, which included two new studies and analyses from prior studies. However, the data was not deemed sufficient to conclude on efficacy, the company saidPLX stock is up by 28% this year and by 120% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/boston-scientific-to-acquire-privately-held-pain-solutions-developer-nalu-medical-for-about-533-million/ch6se8ER38d">Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?

However, Protalix CEO said that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease.

Equity

Wall Street analysts downgraded Regulus Therapeutics on Wednesday following its acquisition by Swiss drugmaker Novartis, citing limited room for upside after the deal valued Regulus at up to $1.7 billion.JonesResearch cut its rating to ‘Hold’ from ‘Buy’ and lowered its price target to $7 from $8, calling the offer “highly favorable” in light of Regulus’ upcoming Phase 3 trial financing needs, according to The Fly.Canaccord Genuity also&nbsp;reportedly downgraded the stock to ‘Hold,’ slashing its target to $11 from $28.&nbsp;Meanwhile,&nbsp;Wells Fargo reportedly cut its rating on Regulus to ‘Equal Weight’ from ‘Overweight,’ raising its target to $9 from $6 to reflect the contingent value right (CVR) component. Leerink Partners and Oppenheimer issued similar downgrades.Under the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regulus-therapeutics-stock-rockets-on-novartis-buy-offer/chXTfRKRbiP">agreement</a>, Regulus shareholders will receive $7 per share in cash and an additional $7 via a CVR, contingent on U.S. regulatory approval of its lead candidate, farabursen.&nbsp;The upfront payment represents a 108% premium to Regulus’ April 29 closing price and a 274% premium to its 60-day volume-weighted average.&nbsp;The transaction, unanimously approved by both companies’ boards, is expected to close in the second half of 2025, pending regulatory approvals and majority shareholder tender.Shares of Regulus surged to their highest levels since 2021 following the news and are up 6.4% year-to-date, while Novartis has gained 4.8%, both outperforming broader markets.The Dow is down 4.1%, the S&amp;P 500 has lost 5.1%, and the Nasdaq is off 1.6% over the same period.On Stocktwits, 24-hour message volume for Regulus jumped by 2,863% amid “extremely bullish” sentiment.One user congratulated Regulus shareholders, particularly recent buyers, and suggested that the growing interest in rare diseases could make companies like Protalix BioTherapeutics, Zevra Therapeutics, and Esperion Therapeutics potential targets going forward.<stembedurl>https://stocktwits.com/OldManLogan/message/613115970</stembedurl>Another Stocktwits user speculated that Regulus shares could double from current levels, fueled by FDA-related optimism and the potential for a competing bid to top Novartis' offer.<stembedurl>https://stocktwits.com/ST_Tropez_Trading/message/613203730</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regulus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference PR Newswire CARMIEL, Israel, Feb...

Pluxee shares jump 11% on strong Q1 operating revenue growth

Investing.com -- Pluxee NV (EPA:PLX) reported 12.1% organic growth in first-quarter operating revenue, beating market expectations, and sending its shares soaring 11% in European trading Wednesday.

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE: PLX) (Protalix) on behalf of the companys shareholders. Since May 2023, shares of Protalix common stock have...

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference...

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Protalix BioTherapeutics Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

PLX
Protalix BioTherapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest PLX News

PLXProtalix BioTherapeutics Inc.